Cohance Lifesciences Limited (NSE:COHANCE)

Cohance Lifesciences Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	12,588	11,976	10,514	13,403	13,202	10,097
Other Revenue	-	-	-	-	-	-0
Revenue	12,588	11,976	10,514	13,403	13,202	10,097
Revenue Growth (YoY)	34.71%	13.91%	-21.56%	1.52%	30.75%	21.10%
Cost of Revenue	2,993	3,757	3,716	5,882	5,741	4,372
Gross Profit	9,595	8,219	6,797	7,521	7,461	5,725
Selling, General & Admin	2,870	2,562	1,396	1,218	1,024	784.18
Research & Development	-	-	-	-	103.55	110.58
Other Operating Expenses	3,104	1,601	1,311	561.82	526.62	415.35
Operating Expenses	6,888	4,938	3,253	2,259	2,045	1,626
Operating Income	2,708	3,281	3,544	5,262	5,416	4,099
Interest Expense	-123.3	-123.5	-74.5	-128.11	-62.31	-91.44
Interest & Investment Income	-	12.7	19.3	58.32	0.69	2.68
Earnings From Equity Investments	-	-	-	-	411.12	537.36
Currency Exchange Gain (Loss)	-	116.6	81.2	214.38	164.21	95.59
Other Non Operating Income (Expenses)	533.2	12.4	66.8	32.9	0.02	0
EBT Excluding Unusual Items	3,118	3,299	3,637	5,439	5,930	4,643
Merger & Restructuring Charges	-	-302.6	-31.1	-	-	-
Gain (Loss) on Sale of Investments	-	409.6	449.1	156.87	636.14	33.28
Gain (Loss) on Sale of Assets	-	-1.1	-0.7	-0.07	106.03	0.34
Other Unusual Items	-81	34.3	2.7	1.17	3.73	-
Pretax Income	3,037	3,439	4,057	5,597	6,676	4,677
Income Tax Expense	678.5	791.5	1,054	1,484	2,138	1,053
Earnings From Continuing Operations	2,358	2,648	3,003	4,113	4,538	3,623
Minority Interest in Earnings	55.8	31	-	-	-	-
Net Income	2,414	2,679	3,003	4,113	4,538	3,623
Net Income to Common	2,414	2,679	3,003	4,113	4,538	3,623
Net Income Growth	0.39%	-10.79%	-26.99%	-9.37%	25.24%	14.30%
Shares Outstanding (Basic)	255	255	255	255	255	255
Shares Outstanding (Diluted)	257	256	255	255	255	255
Shares Change (YoY)	0.94%	0.49%	-	-	-	-
EPS (Basic)	9.47	10.52	11.80	16.16	17.83	14.23
EPS (Diluted)	9.40	10.45	11.80	16.16	17.83	14.23
EPS Growth	-0.55%	-11.45%	-26.99%	-9.37%	25.27%	14.30%
Free Cash Flow	-	1,325	3,329	1,713	2,548	2,717
Free Cash Flow Per Share	-	5.18	13.08	6.73	10.01	10.67
Dividend Per Share	-	-	-	-	2.000	2.000
Dividend Growth	-	-	-	-	-	60.00%
Gross Margin	76.22%	68.63%	64.65%	56.11%	56.51%	56.70%
Operating Margin	21.51%	27.40%	33.71%	39.26%	41.02%	40.59%
Profit Margin	19.18%	22.37%	28.56%	30.69%	34.37%	35.88%
Free Cash Flow Margin	-	11.06%	31.66%	12.78%	19.30%	26.91%
EBITDA	3,547	4,056	4,090	5,726	5,795	4,407
EBITDA Margin	28.18%	33.87%	38.90%	42.72%	43.89%	43.65%
D&A For EBITDA	839.11	774.9	546	464.6	378.64	308.36
EBIT	2,708	3,281	3,544	5,262	5,416	4,099
EBIT Margin	21.51%	27.40%	33.71%	39.26%	41.02%	40.59%
Effective Tax Rate	22.35%	23.01%	25.98%	26.52%	32.02%	22.52%
Revenue as Reported	13,121	12,561	11,133	13,867	14,126	10,240
Advertising Expenses	-	57.2	34.8	34.89	18.83	18.37

Source: S&P Global Market Intelligence. Standard template. Financial Sources.